SCHEMBL980134

SCHEMBL980134

COc1ccc(CC(=O)N2CCC(c3ccccc3OC)=N2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
RAB9A P51151 3/20 0.54
HPGD P15428 3/20 0.54
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
HSD17B10 Q99714 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ATM Q13315 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ABCB1 P08183 1/20 0.45
ABCC1 P33527 1/20 0.45
LMNA P02545 1/20 0.44
PDE5A O76074 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981598 0.92 KDM4E (0.48) ALDH1A1SMN1; SMN2RAB9AHPGDTDP1
SCHEMBL982142 0.91 L3MBTL1 (0.43) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL981528 0.89 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL982292 0.88 SIGMAR1 (0.47) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL979315 0.88 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL980436 0.87 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL981809 0.87 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2RAB9AHPGDL3MBTL1
SCHEMBL980061 0.85 KMT2A (0.48) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL981993 0.84 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT
SCHEMBL980150 0.83 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2RAB9AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
WO-2007019933-A1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885SMN1; SMN2 4245/4885RAB9A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.